Yes, anxiety medications can significantly increase fall risk in people with dementia, and this danger deserves serious attention from caregivers and medical teams. Anxiety drugs work by depressing the central nervous system—slowing brain activity to calm anxious thoughts—but this same mechanism also impairs balance, coordination, and reaction time. When combined with the cognitive and physical changes already present in dementia, the result can be catastrophic. A person with moderate dementia taking a benzodiazepine for anxiety might feel steadier in the moment because their anxiety has eased, but their brain’s ability to catch themselves mid-stumble, adjust their gait on uneven ground, or respond to a sudden obstacle has deteriorated.
The risk isn’t theoretical. An 82-year-old woman with Alzheimer’s disease was prescribed lorazepam for agitation related to her cognitive decline. Within two weeks of starting the medication, she fell twice—once in the bathroom and once while walking to the kitchen. The first fall resulted in a hip fracture that required surgery and led to permanent mobility loss. Her daughter later learned that benzodiazepines are among the most common medications linked to falls in older adults with dementia, yet her mother’s doctor had not discussed fall risk during the initial prescription conversation.
Table of Contents
- How Do Anxiety Medications Increase Fall Risk in Dementia Patients?
- Which Anxiety Medications Carry the Highest Fall Risk?
- How Does Dementia Itself Contribute to Fall Risk When Combined With Anxiety Medication?
- How Should Anxiety Be Managed Safely in Dementia Without Increasing Fall Risk?
- What About Drug Interactions and Multiple Medications?
- What Warning Signs Suggest an Anxiety Medication Is Increasing Fall Risk?
- What Happens When Anxiety Medication Is Reduced or Stopped?
How Do Anxiety Medications Increase Fall Risk in Dementia Patients?
Anxiety medications, particularly benzodiazepines and certain other sedating drugs, lower central nervous system activity to reduce anxiety symptoms. This sedation affects multiple systems involved in balance and coordination: the cerebellum, which controls movement timing; the vestibular system, which manages balance; and the proprioceptive system, which tells your body where it is in space. In someone without dementia, these systems might compensate for mild sedation. But dementia has already damaged the brain’s ability to integrate these signals and make split-second corrections.
The combination creates a two-hit problem that dramatically raises fall risk. Research consistently shows that benzodiazepines increase fall risk by 40 to 50 percent in older adults, and the risk climbs even higher—sometimes doubling—in people with cognitive impairment. The medications don’t just cause sedation; they also impair judgment and increase the likelihood of taking physical risks without fear or awareness of danger. A person with dementia on anxiety medication might not recognize that the hallway is dimly lit or that they’re moving too quickly, whereas someone without cognitive decline might slow down or reach for a wall. The combination of impaired balance, reduced awareness, and slowed reaction time creates a nearly perfect storm for falls.
Which Anxiety Medications Carry the Highest Fall Risk?
Benzodiazepines—drugs like lorazepam (Ativan), alprazolam (Xanax), diazepam (Valium), and clonazepam (Klonopin)—are the most notorious for causing falls in older adults with dementia. These medications are particularly dangerous because they accumulate in the body over time, especially in people with slowed metabolism or liver problems common in aging. Long-acting benzodiazepepines like diazepam stay in the system for days, creating a persistent sedation that never fully clears. Even at low doses, benzodiazepines in a person with dementia can impair balance enough to tip a previously stable person into the fall-prone category. SSRIs (selective serotonin reuptake inhibitors) like sertraline and escitalopram, sometimes used to treat anxiety in dementia, carry a lower fall risk than benzodiazepines but are not risk-free.
They can cause dizziness, low blood pressure upon standing, and confusion—all factors that increase falls. Buspirone, a non-controlled anti-anxiety medication, is generally considered safer for fall risk, but it’s less effective for acute anxiety and takes weeks to work. The limitation here is that many caregivers and doctors reach for benzodiazepines because they work immediately and are inexpensive, even though slower-acting alternatives might be safer in dementia. A 78-year-old with vascular dementia started on sertraline for anxiety experienced lightheadedness when standing up, leading to a near-fall when she reached for the bathroom door frame. After three weeks on the medication, she fell while walking from the living room to the kitchen.
How Does Dementia Itself Contribute to Fall Risk When Combined With Anxiety Medication?
Dementia damages the very brain regions responsible for preventing falls—the frontal lobe (planning and impulse control), the basal ganglia (automatic movement patterns), and the parietal lobe (spatial awareness). People with moderate to advanced dementia already walk more slowly, shuffle their feet, have poor balance, and lack awareness of their surroundings. They may not remember where the bathroom is, even if they’ve lived in the same house for ten years, leading to wandering and environmental risks. When you add an anxiety medication that further impairs alertness and coordination, the person loses additional layers of protection. The interaction is multiplicative, not just additive.
A person with early dementia on no medications might have a 5 percent annual fall risk. The same person on an anxiety medication might jump to a 15 or 20 percent annual risk. In absolute terms, that means a person who might expect one fall every 20 years now faces one every 5 to 7 years. For someone already fragile, a single fall can trigger a cascade: hospitalization, immobilization, deconditioning, and often a permanent loss of independence. The warning sign is not just one fall but any change in gait, stability, or confidence after starting a new medication.
How Should Anxiety Be Managed Safely in Dementia Without Increasing Fall Risk?
The safest approach starts with non-medication strategies: reducing environmental triggers for anxiety, creating predictable routines, using validation and reassurance rather than arguing about reality, and ensuring adequate sleep and physical activity. Many episodes of anxiety in dementia are driven by confusion, fear of the unknown, or unmet physical needs like pain or hunger. Addressing these root causes often reduces anxiety more effectively than medication and carries no fall risk. A 75-year-old with Lewy body dementia was taking lorazepam three times a day for agitation; after her daughter recognized that the agitation spiked around 4 p.m. (sundowning) and the woman was actually hungry because dinner was delayed, they adjusted meal times and reduced the medication dose.
The anxiety decreased, falls stopped, and the woman remained more alert. When medication is necessary, the goal should be using the lowest effective dose for the shortest time possible, with regular reassessment. Some physicians now prescribe alternatives to benzodiazepines—such as low-dose antipsychotics (though these carry their own risks), buspirone, or specific SSRIs like citalopram at cautious doses. The tradeoff is that these alternatives may take two to four weeks to work or may be less effective than a benzodiazepine for immediate anxiety relief. For caregivers, this means tolerating some uncomfortable anxiety in the short term to prevent a fall that could cause fracture, hospitalization, or loss of function. Close physical supervision, removing tripping hazards, installing grab bars, and ensuring good lighting become even more critical when anxiety medication is necessary.
What About Drug Interactions and Multiple Medications?
Most people with dementia take multiple medications: blood pressure drugs, cholesterol medications, pain relievers, and sleep aids, in addition to any medication for dementia itself (like donepezil). When anxiety medication is added to this mix, the risk compounds. A medication that mildly lowers blood pressure combined with an anxiety drug that causes dizziness can lead to a blood pressure drop severe enough to cause fainting. Pain medications and sleep aids are themselves fall risks; combining them with benzodiazepines amplifies sedation. A 79-year-old man with Alzheimer’s was on a statin, a blood pressure medication, donepezil, and tramadol for arthritis pain. His doctor prescribed alprazolam for anxiety.
Three days into the new medication, he fell while getting out of bed—the combined effect of all these drugs had left him so sedated that he couldn’t coordinate the simple movement of standing. The limitation of current prescribing is that primary care doctors often do not have full visibility into all the medications a person is taking, especially if they see multiple specialists. A cardiologist prescribes one drug, a neurologist prescribes another, and a primary care doctor adds a third without anyone doing a full inventory of fall risk. This is called polypharmacy—the use of multiple medications—and it’s a known danger in older adults. Caregivers should request a “brown bag review” where all medications in bottles are brought to an appointment so a pharmacist can assess interactions. Some interactions can’t be avoided, but awareness allows for closer monitoring and dose adjustments.
What Warning Signs Suggest an Anxiety Medication Is Increasing Fall Risk?
Watch for changes in gait within the first two weeks of starting an anxiety medication: shuffling, wider stance, reduced arm swing, or moving as if the floor might tilt unexpectedly. Dizziness, especially upon standing, is a red flag. Confusion or increased confusion beyond baseline dementia can indicate over-medication. Some people become less able to follow commands or respond to their name. Others show increased tremor, slurred speech, or loss of appetite.
A person who was previously able to walk independently but begins holding walls or furniture after starting medication should trigger an urgent medication review. Unexplained falls in the weeks after starting a new anxiety drug are almost certainly related. Changes in behavior may also indicate medication problems. A person who becomes more withdrawn, less responsive, or “zombie-like” might be experiencing excessive sedation. Paradoxically, some people—particularly those with certain types of dementia—experience increased agitation or confusion when started on benzodiazepines, a reaction that may lead caregivers to request a higher dose, worsening the problem. The lesson is that any significant change in function or behavior within two to four weeks of medication changes should prompt communication with the prescribing physician, not acceptance as a new normal.
What Happens When Anxiety Medication Is Reduced or Stopped?
If fall risk becomes unacceptable, anxiety medication should be tapered slowly, not stopped abruptly. Benzodiazepines especially can cause serious withdrawal symptoms—seizures, increased anxiety, tremor, confusion—if stopped suddenly. A safe taper typically involves reducing the dose by 10 to 25 percent every one to two weeks while non-medication anxiety management is increased. During the taper, anxiety may temporarily worsen, and caregivers should expect this as the brain rebalances. Environmental supports and supervision need to increase during this period. A 71-year-old woman with vascular dementia took lorazepam for three years; her care team decided to taper it because she had fallen twice in six months.
Over eight weeks, they reduced the dose gradually while her daughter spent more time with her daily, used calm reassurance, and adjusted routines to reduce anxiety triggers. By the end of the taper, the woman had no falls in the subsequent four months, and her alertness and social engagement improved noticeably. Not all anxiety medications need to be stopped. If an SSRI or buspiron is working without causing falls, it may be continued indefinitely. The key is matching the specific medication to the individual’s needs and tolerances. Some people do well on a very low dose of benzodiazepine—just enough to take the edge off without causing sedation—but this requires careful monitoring and realistic acceptance of some ongoing anxiety. The decision to continue, reduce, or stop should involve the person with dementia (if they have capacity to understand), their caregiver or proxy decision-maker, their primary care doctor, and ideally a pharmacist who can review all medications together.
- —
